Please login to the form below

Not currently logged in
Email:
Password:

Merck u-turns on NDA for HIV drug

Merck & Co has said it will not submit a New Drug Application (NDA) to the US FDA for its HIV treatment, vicriviroc, at this time

Merck & Co has said it will not submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its HIV treatment, vicriviroc, at this time.

The company has made the announcement after the drug failed to meet the primary efficacy endpoint in two phase III trials in treatment-experienced HIV-infected patients. These particular trials involved a high percentage of patients who had three or more active drugs in their optimised background therapy regimen.

Vicriviroc was one of the drugs acquired by Merck when it purchased Schering-Plough for $41.4bn last year.

Merck will continue with current phase II trials investigating vicriviroc as a therapy in treatment-naïve HIV-infected patients. In addition, those treatment-experienced patients from the phase III who have responded well to treatment with the drug, will continue to have access to the medicine.

21st January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics